Sparingvision

sparingvision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. sparingvision is developing spvn06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration. there is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects 40,000 people in france and nearly 2 million worldwide. sparingvision is a spin-off of the paris vision institute. bpifrance, foundation fighting blindness (us) and voir & entendre foundation invested €15.5 million in the company. sparingvision was laureate and grand prize of i-lab 2017, the national contest for the creation of innovative companies, and is part of the first selection of companies of hub heath tech launched by bpifrance in december 2017. sparingvision has been created on strong expertise and technology from institut de la vision in paris. s